Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.
Axxam acquires Hit Discovery Constance Read More »
Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.
Symegold library for drug discovery services Read More »
Bresso (Italy), Villigen (Switzerland) and Nijmegen (the Netherlands) – Axxam, leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
Axxam announces the launch of Libra Therapeutics to develop novel therapies targeting neurodegenerative diseases Sept 24, 2020 Milan (Italy) – Axxam is proud to announce that Libra Therapeutics, a privately held US biotech company founded in mid-2019 by Axxam and focused to develop novel therapies for patients suffering from neurodegenerative diseases as amyotrophic lateral sclerosis
Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy – Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading discovery research company, announce a collaboration for the identification of novel small molecule therapies for Alzheimer’s disease (AD), based on
Selonterra and Axxam Enter into Drug Discovery Collaboration Read More »
Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs. Thanks to its expertise in early phase discovery biology, Axxam
Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications Read More »
Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2 Apr 30, 2020 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced its commitment to support the identification of antiviral therapies to treat the severe acute respiratory syndrome COVID-19, caused by the Coronavirus SARS-CoV-2. Axxam is developing a series of in-vitro biochemical
Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2 Read More »
Axxam and ERS Genomics announce CRISPR-Cas9 license agreement to enhance discovery services Apr 2, 2020 Milan (Italy) and Dublin (Ireland) – 2 April 2020 – ERS Genomics Limited (“ERS Genomics”), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (“Axxam”), a leading discovery